Skip to main content
BEAM
NASDAQ Life Sciences

Beam's Risto-cel Clears Pivotal Sickle Cell Trial, BLA Filing Set for Year-End

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$27.4
Mkt Cap
$2.796B
52W Low
$20.23
52W High
$38.26
52W Position info
35% above low
Off High info
28% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

BEAM sits 35% above its 52-week low of $20.23.

Summary

Beam's BEACON Phase 1/2 trial of risto-cel hit both its primary efficacy and safety endpoints in sickle cell disease, and every secondary endpoint including freedom from hospitalization for vaso-occlusive crises. The single-arm trial in SCD patients with severe vaso-occlusive crises measured its primary efficacy endpoint as freedom from severe VOCs for at least 12 consecutive months, on a data cut date of Oct. 20, and full BEACON results will be disclosed at a medical meeting next year. That is the full package a gene-editing program needs before filing, and Beam says it will submit a BLA to the FDA by year-end 2026. This is the most important clinical readout in the company's history and lands on a $2.8B market cap stock trading at $27.40, though shares fell more than 10% Tuesday despite the positive readout; UBS reiterated Hold with a $28 target, noting investor focus remains on the AATD program. It also comes after a rough stretch: shares fell 9% in September on disappointing BEAM-302 AATD data, and the Q3 report on November 3 showed a $134.4M loss with $1.0B in cash. The cash covers the filing and launch prep, so the BLA submission by year-end is the next hard checkpoint.

Updated with a Seeking Alpha report · What changed

Updates

  1. · Seeking Alpha — Beam shares fell more than 10% Tuesday despite the positive BEACON readout; UBS reiterated Hold with a $28 target, noting investor focus remains on the AATD program.

    • Trial Design — The trial was a single-arm study in SCD patients with severe vaso-occlusive crises.
    • Primary Endpoint — The primary efficacy endpoint was freedom from severe VOCs for at least 12 consecutive months, on a data cut date of Oct. 20.
    • Results Disclosure — Full BEACON results are planned to be disclosed at a medical meeting next year.
    All 4 details
    • Primary efficacy endpoint: freedom from severe VOCs for at least 12 consecutive months
    • Data cut date: Oct. 20
    • Single-arm trial in SCD patients with severe vaso-occlusive crises
    • Full BEACON results to be disclosed at a medical meeting next year

At the time of this announcement, BEAM was trading at $27.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $20.23 to $38.26. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

BEAM - Latest Insights

BEAM
Nov 03, 2026, 8:34 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $25.31
Real-time Price: $24.38 info
Change: -$0.930 (-4%) info
Market Cap: $2.523B info
BEAM
Nov 03, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $25.87
Real-time Price: $24.38 info
Change: -$1.49 (-6%) info
Market Cap: $2.523B info
BEAM
Oct 13, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $25.47
Real-time Price: $24.38 info
Change: -$1.09 (-4%) info
Market Cap: $2.523B info
BEAM
Sep 08, 2026, 3:24 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $26.94
Real-time Price: $24.38 info
Change: -$2.55 (-9%) info
Market Cap: $2.523B info
BEAM
Sep 08, 2026, 9:22 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $25.95
Real-time Price: $24.38 info
Change: -$1.57 (-6%) info
Market Cap: $2.523B info